Tallow derivative use regardless of country's TSE/BSE status recommended by FDA cmte.
This article was originally published in The Tan Sheet
TALLOW DERIVATIVE SOURCE IRRESPECTIVE OF COUNTRY's BSE STATUS RECOMMENDED by a narrow vote by FDA's Transmissible Spongiform Encephalopathies Advisory Committee at a meeting in Bethesda, Md. April 15-16. The committee voted 6-5 to allow for the sourcing of tallow derivatives in drugs, nutritional supplements, foods and cosmetics "from any country, irrespective" of its bovine spongiform encephalopathy (e.g., "mad cow disease") status, Committee Chairman Paul Brown, MD, National Institute of Neurological Disorders & Stroke, stated. The advisory group's recommendation would reverse current FDA guidelines, which disallow bovine source materials for the manufacturing of tallow derivatives from countries where TSE/BSE occur.
You may also be interested in...
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning